Management

Alvotech HQ Building Reykajvik with Hallgrimskirkja in the background

The Factory Works. Now the Cash Has to Follow

Alvotech’s Reykjavík factory is now FDA-approved and producing more efficiently, but revenue remains below expectations and cash is under pressure. Meeting 2026 guidance requires an exceptionally strong fourth quarter, potentially dependent on approvals and licensing deals. High debt, interest, investment, and working-capital needs make adjusted EBITDA misleading. Future focus: cash generation, contract assets, and financing risk.